BeiGene and SpringWorks Globally Signs Clinical Agreement to Target Advanced Solid Tumours

 BeiGene and SpringWorks Globally Signs Clinical Agreement to Target Advanced Solid Tumours

BeiGene’s Brukinsa (zanubrutinib) Receives the US FDA’s Accelerated Approval for Patients with Mantle Cell Lymphoma Who Received At least One Prior Therapy

Shots:

  • The agreement involves assessing safety, efficacy and tolerability of BeiGene’s RAFi dimer, lifirafenib (BGB-283) and SpringWorks’ MEKi (PD-0325901), in patients with advanced solid tumours
  •  BeiGene will look forward for onset of P-Ib trial for advanced solid tumours while SpringWorks will oversee fixed dosing formulation in trial
  • The P-Ib trial is expected to initiate in Q1’19 while the costing and governance responsibilities of the trial will be shared equally b/w both the companies

Click here to read full press release/ article | Ref: BeiGene | Image:  Capital Watch

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post